Quince Therapeutics Inc [QNCX] stock prices are up 0.62% to $1.61 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The QNCX shares have gain 7.33% over the last week, with a monthly amount glided 53.33%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Quince Therapeutics Inc [NASDAQ: QNCX] stock has seen the most recent analyst activity on March 24, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $10.
The stock price of Quince Therapeutics Inc [QNCX] has been fluctuating between $0.51 and $2.45 over the past year. Quince Therapeutics Inc [NASDAQ: QNCX] shares were valued at $1.61 at the most recent close of the market.
Analyzing the QNCX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -1.73 and Total Capital is -0.62. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.84.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5283 points at the first support level, and at 1.4467 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6733, and for the 2nd resistance point, it is at 1.7367.
Ratios To Look Out For
It’s worth pointing out that Quince Therapeutics Inc [NASDAQ:QNCX]’s Current Ratio is 4.05. Further, the Quick Ratio stands at 4.05, while the Cash Ratio is 0.93.
Transactions by insiders
Recent insider trading involved Thye Dirk, CEO AND CHIEF MEDICAL OFFICER, that happened on Aug 30 ’24 when 77000.0 shares were purchased. CEO AND CHIEF MEDICAL OFFICER, Thye Dirk completed a deal on Aug 29 ’24 to buy 77500.0 shares. Meanwhile, PRESIDENT Ryan Charles S. bought 48387.0 shares on Aug 20 ’24.
